C-11 Choline uses a radioisotope to detect sites of recurrent prostate cancer that conventional imaging, such as CAT or MRI scans, can’t. The C-11 Choline is injected into the patient prior to a PET/CT scan. Cancer cells absorb the C-11 Choline and light up, allowing physicians to pinpoint the location of these cells to more effectively treat recurrent prostate cancer.
“A traditional CAT scan or MRI is not sensitive enough to find cancer when it is very small,” said Sean D. Pierce, MD, chairman of the department of radiology at HackensackUMC. “C-11 Choline shows 80-90 percent specificity, which means we can pick up very small areas of cancer with much more sensitivity, allowing us to better target our treatment of that patient.”
C-11 Choline is a biomarker approved by the U.S. Food and Drug Administration and is reimbursed by CMS.
“I congratulate the radiology team members, under the direction of Dr. Pierce, for their commitment to seeking the most advanced technology to treat our patients,” said Ihor S. Sawczuk, MD, president of HackensackUMC. “This new technology is giving us a lead time that no other institution in New Jersey has. We are able to treat the cancer at a much earlier stage to give the patient more specific and targetable therapy, and overall, the chance of a better outcome.”
More articles on quality:
Wisconsin to prevent epidemic of older adults from falling through state programs
Maternal mortality up in US, down worldwide
Addressing 30-day readmissions of PCI patients may not improve mortality rates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
